138 related articles for article (PubMed ID: 18488861)
1. [Cost-effectiveness of angiotensin receptor blockers in patients with type 2 diabetes mellitus and nephropathy in Israel].
Berar-Yanay N; Leshno M; Hertzeanu L; Weintrob N
Harefuah; 2008 Mar; 147(3):211-5, 278. PubMed ID: 18488861
[TBL] [Abstract][Full Text] [Related]
2. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of losartan in diabetic nephropathy: a Greek perspective.
Stafylas PC; Sarafidis PA; Lasaridis AN; Tsakni E; Niakas DA; Dombros NV; Grekas DM; Bakris GL
J Nephrol; 2007; 20(6):703-15. PubMed ID: 18046673
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of angiotensin receptor blockers in type 2 diabetes, hypertension, and nephropathy.
Ravera M; Re M; Vettoretti S
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S44-8. PubMed ID: 16565246
[TBL] [Abstract][Full Text] [Related]
6. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
[TBL] [Abstract][Full Text] [Related]
7. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
[TBL] [Abstract][Full Text] [Related]
8. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
Burgess ED; Carides GW; Gerth WC; Marentette MA; Chabot I;
Can J Cardiol; 2004 May; 20(6):613-8. PubMed ID: 15152291
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany.
Adarkwah CC; Gandjour A
Int J Technol Assess Health Care; 2010 Jan; 26(1):62-70. PubMed ID: 20059782
[TBL] [Abstract][Full Text] [Related]
10. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.
Winkelmayer WC; Zhang Z; Shahinfar S; Cooper ME; Avorn J; Brenner BM
Diabetes Care; 2006 Oct; 29(10):2210-7. PubMed ID: 17003295
[TBL] [Abstract][Full Text] [Related]
12. [Economic impact of Losartan use in type 2 diabetic patients with nephropathy].
González F F; Fuentes C V; Castro H C; Santelices L JP; Lorca H E
Rev Med Chil; 2009 May; 137(5):634-40. PubMed ID: 19701552
[TBL] [Abstract][Full Text] [Related]
13. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy.
Clark WF; Churchill DN; Forwell L; Macdonald G; Foster S
CMAJ; 2000 Jan; 162(2):195-8. PubMed ID: 10674051
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.
Coyle D; Rodby R; Soroka S; Levin A; Muirhead N; de Cotret PR; Chen R; Palmer A
Clin Ther; 2007 Jul; 29(7):1508-23. PubMed ID: 17825702
[TBL] [Abstract][Full Text] [Related]
15. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
Palmer AJ; Valentine WJ; Tucker DM; Ray JA; Roze S; Annemans L; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH; Laville M
Curr Med Res Opin; 2006 Nov; 22(11):2095-100. PubMed ID: 17076969
[TBL] [Abstract][Full Text] [Related]
16. Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial.
Agha A; Amer W; Anwar E; Bashir K
Saudi J Kidney Dis Transpl; 2009 May; 20(3):429-35. PubMed ID: 19414946
[TBL] [Abstract][Full Text] [Related]
17. ARBs vs ACE inhibitors for preventing diabetic nephropathy.
Greenwood V
J Fam Pract; 2005 May; 54(5):453; discussion 453-4. PubMed ID: 15865904
[No Abstract] [Full Text] [Related]
18. Pharmaco-economic consequences of losartan therapy in patients undergoing diabetic end stage renal disease in EU and USA.
de Portu S; Citarella A; Cammarota S; Menditto E; Mantovani LG
Clin Exp Hypertens; 2011; 33(3):174-8. PubMed ID: 21466388
[TBL] [Abstract][Full Text] [Related]
19. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
Remuzzi G; Ruggenenti P; Perna A; Dimitrov BD; de Zeeuw D; Hille DA; Shahinfar S; Carides GW; Brenner BM;
J Am Soc Nephrol; 2004 Dec; 15(12):3117-25. PubMed ID: 15579515
[TBL] [Abstract][Full Text] [Related]
20. Uremia (end-stage renal disease): how cost-effective are preventive strategies?
Glassock RJ
J Ren Nutr; 2010 Sep; 20(5 Suppl):S131-4. PubMed ID: 20797562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
